论文部分内容阅读
目的观察氟哌噻吨美利曲辛片(黛力新)对帕金森病患者抑郁症状的改善作用。方法将56例帕金森病患者按照随机数字表法随机分为观察组和对照组各28例。观察组采用黛力新治疗;对照组采用常规方法治疗。比较2组患者汉密尔顿抑郁量表(HAMD)评分、抑郁症状的临床疗效及不良反应。结果 2组患者治疗前的HAMD评分比较差异无统计学意义(P>0.05)。治疗后观察组1、2、4、6周时的HAMD评分均低于对照组,总有效率为96.43%高于对照组的64.29%,不良反应发生率明显低于对照组,差异均有统计学意义(P<0.05)。结论黛力新能够有效改善帕金森病患者的抑郁症状,疗效显著、安全可靠。
Objective To observe the effect of flupentixol and melitracen tablets (Deanxit) on the improvement of depressive symptoms in patients with Parkinson’s disease. Methods Fifty-six patients with Parkinson’s disease were randomly divided into observation group and control group according to random number table method. The observation group was treated with Deanin, while the control group was treated by conventional method. The Hamilton Depression Rating Scale (HAMD) score, the clinical efficacy and adverse reactions of depressive symptoms in two groups were compared. Results There was no significant difference in HAMD scores between the two groups before treatment (P> 0.05). At 1, 2, 4 and 6 weeks after treatment, the HAMD scores of the observation group were lower than those of the control group, the total effective rate was 96.43%, 64.29% of the control group, and the incidence of adverse reactions was significantly lower than that of the control group Significance (P <0.05). Conclusion Deanxit can effectively reduce the symptoms of depression in patients with Parkinson’s disease, the effect is significant, safe and reliable.